RE:RE:RE:Denali Hunter DataI wouldn't be too quick to discount Denali, prophetofphax. They're the company worth USD $3.4 billion today. Bioasis is worth CDN $12.3 million today.
So, who gets Bioasis's Hunter xB3-LSD drug? Does it already belong to Chiesi? I don't know but that wouldn't surprise me, given the secrecy and obliqueness of Bioasis's documentation and filings.
Would Protalix play a part in cheap production with ProCellEx? Where is Chiesi after more than two years?
As far as Bioasis having a "strategic portfolio of LSDs with Chiesi" I think that Bioasis sold the rights to those LSDs with only very low milestone payments possibly due and probably a very low royalty rate. That is NOT a strategic partnership. That's like buying a pickup truck and claiming you're in a strategic partnership with the automaker.
Bioasis's only claim to Fabry is with xB3-004 (IL1-Ra) and its treatment of neuropathic pain caused by Fabry, totally different than an enzyme replacement therapy for the disease.
jd